Twist's proof points

Why Twist opted for a $60M venture round rather than IPO

Twist Bioscience Corp. is expanding its drug discovery and data storage businesses and ramping up its core DNA synthesis business to build a stronger case for an IPO.

When Twist raised a $61 million series D in January 2016 it was expected to

Read the full 437 word article

User Sign In